Shatavari extract study reports improvements in women’s sexual health - Nutraceutical Business Review

DennyOkay, this is the one I wanted to get into today: Shatavari extract study reports improvements in women’s sexual health. Where do you land on it?

FarrahSeventy women isn't enough to prove anything beyond the margins of error, especially when half of them got a sugar pill. A woman sitting in her doctor's office can't tell if she feels better because of the herb or because she expected to. We're looking at noise until someone runs a much bigger test.

DennyBut hold on, Farrah, the trial was double-blind, meaning neither the doctors nor the participants knew who got the real thing. That kills the expectation factor you’re worried about. And three hundred milligrams daily showing up alongside better sleep and less fatigue suggests there’s actually something going on biologically, not just in their heads.

FarrahDouble-blind doesn't fix the fact that the whole group started out with low sexual desire, so any shift in mood or energy looks like a win even if the body didn’t change. The sleep benefit might just mean they felt less anxious about taking a daily supplement rather than the herb relaxing their muscles. Seven weeks is barely enough time to rule out normal fluctuations in how a woman’s body cycles through the month.

DennyPicture a woman who hasn't felt aroused in months starting this routine, and by week six she’s sleeping through the night and actually has the energy to talk to her partner without feeling drained. That combination of restored moisture plus lifted fatigue points to a real physiological shift in how her body handles stress hormones, not just a mood bump. You can’t fake consistent vaginal hydration changes over seven weeks; that’s tissue responding to something tangible.

FarrahPicture a woman who starts the trial feeling pretty lousy overall, maybe dealing with mild depression or seasonal blues, and the act of committing to a strict daily schedule gives her a sense of control she’d been missing. Her sleep improves because her anxiety drops, not because the root relaxes her tissues, and that calmer state makes her notice arousal again simply because she isn't exhausted.

DennyWait, thirty days is barely a blip compared to a full menstrual cycle. How did they account for where each participant landed during those eight weeks?

FarrahYou are absolutely right that ignoring the timing within the menstrual cycle could totally muddy the water here, since natural hormone swings happen every single month anyway. What the article leaves hanging is whether they tracked those dates or grouped everyone together regardless of where they were in their cycle, which matters a lot for interpreting those moisture results accurately.

DennyTracking the cycle phase would definitely sharpen those moisture readings, but the real clue hiding in plain sight is that thirty percent of the placebo group reported no change at all while the active group saw broad improvements across sleep, fatigue, and function simultaneously. When three separate biological markers move in lockstep, it stops looking like random fluctuation and starts pointing toward a specific mechanism affecting how the body processes stress.

FarrahThirty percent staying flat in the placebo arm is exactly what you’d expect from seventy tired women getting told to take a pill twice a day—half the room will report “no change” just to be polite. You’re pattern-matching on a sample size smaller than a typical yoga class, Denny, and calling it biology. Broad improvements in self-reported surveys don’t equal tissue-level proof, no matter how neatly the numbers line up on a spreadsheet.

DennyYou're focusing entirely on the internal symptoms, but the bigger story is that Waleria Healthtech is now marketing this as a clinical alternative to prescription treatments for low desire. If they push this into mainstream retail shelves before larger trials confirm safety, we risk normalizing a product that bypasses medical oversight for conditions that often signal deeper hormonal issues needing actual diagnosis.

FarrahThey haven't said that anywhere in the published data yet, so we'd be punishing them for a press release that doesn't exist. A label on a bottle isn't a clinical claim until a doctor writes it down.

DennyThe published paper calls out "reproductive-age women" specifically, which means they likely screened out anyone under investigation for PCOS or thyroid dysfunction. By excluding complex cases, the trial creates a clean dataset that looks more robust than reality, letting the brand imply universal efficacy when it really just works for a narrow slice of healthy bodies.

FarrahScreening for common conditions is standard practice in almost every clinical trial, otherwise you can't isolate what the extract actually does versus what underlying pathology is driving the symptoms. Calling it "clean" ignores that the journal specifies these exclusions precisely so readers know the limits of generalization, not to hide defects. You're accusing them of implying universal efficacy based on a footnote that explicitly narrows the scope.

DennyExcluding comorbidities is standard, sure, but the pattern still holds because the active arm showed consistent gains across function and moisture even among that restricted cohort, suggesting the extract acts on baseline physiology rather than masking disease. That’s enough signal to justify a follow-up trial including complex cases without pretending we’ve solved the whole puzzle yet.

FarrahBaseline physiology sounds impressive, but eight weeks in a hundred-and-fifty-pound trial isn’t enough time to rule out placebo effects settling in. Until a bigger study proves the extract itself drives those changes rather than expectation, we’re just guessing at a mechanism that might not exist. Let’s wait for the data to catch up to the hype before we call this a breakthrough.

DennyI’ll grant you the time constraint, but the fact remains that forty percent of the active group hit significant improvement thresholds where only fifteen percent of the placebo group did, which leaves a statistical gap too wide to dismiss as pure expectation. The real test isn't whether we believe the eight-week window is perfect, but whether Waleria commits to the follow-up trial with expanded cohorts before their next major retail launch.